Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
সব দামের পরিবর্তন →ইঙ্গিত ও ব্যবহার
Lopinavir with Ritonavir is an HIV-1 protease inhibitor combination. It is used together with other antiretroviral medicines to treat HIV-1 infection in adults and in children aged 14 days and older.
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
Lopinavir and Ritonavir tablets may be taken with or without food, swallowed whole and not chewed, broken, or crushed.Adult Patients: 400/100 mg (two 200/50 mg tablets) twice daily, or 800/200 mg (four 200/50 mg tablets) once daily in patients with less than three lopinavir resistance-associated substitutions. Concomitant Therapy in Adults Patients: Dose adjustments of Lopinavir and Ritonavir may be needed when co-administering with efavirenz, nevirapine, or nelfinavir. Do not use once daily administration of Lopinavir and Ritonavir in: HIV-1 infected patients with three or more of the following lopinavir resistance-associated substitutions: L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V. Combination with efavirenz, nevirapine, nelfinavir, carbamazepine, phenobarbital, or phenytoin.
পার্শ্বপ্রতিক্রিয়া
Commonly reported side effects include diarrhea, nausea, vomiting, and elevated triglyceride and cholesterol levels in the blood.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Patients taking Rilovir have shown the following effects. Hepatotoxicity: those with underlying hepatitis B or C, or with marked elevations in transaminase levels before starting treatment, may be at greater risk of developing or worsening transaminase elevations or hepatic decompensation while using Rilovir. QT interval prolongation: cases of QT interval prolongation and torsade de pointes have been reported, though a causal link to Rilovir could not be established. Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and those taking other drugs that prolong the QT interval. PR interval prolongation: Lopinavir plus Ritonavir prolongs the PR interval in some patients, and cases of second or third degree atrioventricular block have been reported. Rilovir should be used with caution in patients who have underlying structural heart disease, pre-existing conduction system abnormalities, ischemic heart disease, or cardiomyopathies, since these patients may be at greater risk of developing cardiac conduction abnormalities. Diabetes mellitus and hyperglycemia: new onset diabetes mellitus, worsening of pre-existing diabetes mellitus, and hyperglycemia have been reported in HIV-1 infected patients receiving protease inhibitor therapy. Some patients required either the start or a dose adjustment of insulin or oral hypoglycemic agents to treat these events, and in some cases diabetic ketoacidosis occurred. Among patients who stopped protease inhibitor therapy, hyperglycemia persisted in some cases. Lipid elevations: treatment with Lopinavir and Ritonavir has led to large increases in total cholesterol and triglyceride concentrations.
নিষেধাজ্ঞা
Lopinavir and Ritonavir should not be used in patients who have previously shown clinically significant hypersensitivity (such as toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, urticaria, or angioedema) to any of its ingredients, including lopinavir and ritonavir. It should also not be given together with drugs that depend heavily on CYP3A for their clearance and for which raised plasma concentrations can lead to serious or life-threatening reactions.